article thumbnail

Brii Bio acquires Vir’s antibody rights for Hepatitis B in Greater China

Pharmaceutical Technology

Following the option exercise, Vir will receive the option exercise fee, regulatory and commercial milestone payments as well as tiered royalties on net product sales from Brii Bio. A widely neutralising monoclonal antibody (mAb), VIR-3434 (BRII-877) acts on the hepatitis B virus (HBV).

Antibody 279
article thumbnail

FDA grants approval for bluebird’s Zynteglo to treat beta-thalassemia

Pharmaceutical Technology

0 genotypes. A genetic blood ailment, beta-thalassemia is caused by beta-globin gene mutations and results in a substantial decline or lack of production of adult haemoglobin. The open-label, single-arm, 24-month Phase III trials enrolled 41 subjects of the age four to 34 years with non-?0/?0

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Twist Bioscience Collaborates with Regeneron for Production of Genotyping by Sequencing Panel to Enable Diverse Genome-wide Screening

BioTech 365

Twist Bioscience Collaborates with Regeneron for Production of Genotyping by Sequencing Panel to Enable Diverse Genome-wide Screening Twist Bioscience Collaborates with Regeneron for Production of Genotyping by Sequencing Panel to Enable Diverse Genome-wide Screening — Population Genetics Sequencing Panel Incorporates … Continue reading (..)

article thumbnail

Congenital fibrinogen deficiency market forecast to reach $800m across 3MM by 2031

Pharmaceutical Technology

Major factors driving this growth include the launch of improved human fibrinogen concentrate (HFC) products, the large market potential for HFC in treating acquired fibrinogen deficiency (AFD), and recent increased demand for blood plasma. HFC products must be administered intravenously in a healthcare setting and carry risks of thrombosis.

Marketing 130
article thumbnail

Bermudagrass versus the armyworm

Scienmag

Striving for a better understanding of pest resistance in experimental lines Credit: Gurjit Singh Tifton, Georgia: A study out of the University of Georgia sought to determine the level of host plant resistance that can be assured by several promising experimental bermudagrass genotypes against potential damages committed by the fall armyworm.

article thumbnail

FDA Makes Low-Risk Determination for Marketing of Products from Genome-Edited Beef Cattle After Safety Review

The Pharma Data

Food and Drug Administration announced it has made a low-risk determination for the marketing of products, including food, from two genome-edited beef cattle and their offspring after determining that the intentional genomic alteration (IGA) does not raise any safety concerns (low-risk determination). Solomon, D.V.M., Source link: [link].

Genome 52
article thumbnail

Risk adjusted net present value: What is the current valuation of Pharma Mar’s Ecubectedin?

Pharmaceutical Technology

Pharma Mar offers in vitro diagnostic products used for detection of virus and bacteria in respiratory infections and human papilloma virus genotypes, among others. The drug candidate is a marine-derived compound. Pharma Mar Overview Pharma Mar discovers, develops and markets marine-derived drugs to treat cancer.

Hormones 100